Treatment strategies for glioblastoma in older patients: age is just a number.
Michael YoussefEthan B LudmirJacob J MandelAkash J PatelAli JalaliJeffrey TreiberJimin WuMary Frances McAleerJohn de GrootPublished in: Journal of neuro-oncology (2019)
Our cohort of elderly GBM patients was predominantly treated with standard of care therapy based on EORTC 22,981. Despite their age, these patients generally tolerated treatment well and had favorable outcomes compared to those reported for patients treated on EORTC 22,981. Based on these findings, using advanced age as the basis for treatment de-escalation or as an exclusionary criterion in clinical trials should be discouraged.
Keyphrases
- end stage renal disease
- newly diagnosed
- clinical trial
- ejection fraction
- chronic kidney disease
- healthcare
- palliative care
- randomized controlled trial
- metabolic syndrome
- patient reported outcomes
- adipose tissue
- open label
- bone marrow
- replacement therapy
- health insurance
- african american
- patient reported
- glycemic control